A pipeline poised 

for significant 

clinical success

By leveraging distinct immune mechanisms, we are building a robust pipeline designed to be best-in-class programs designed to deliver transformational therapies for solid tumors and autoimmune diseases with substantial unmet need.

Transforming T cell redirection therapy with increased precision

name
AGB101 (DLL3)
Small cell lung cancer and neuroendocrine tumors
Discovery Lead 
Optimization IND Enabling Phase 1/1b
4Q26
Phase 1
AGB103 (CD19)
Autoimmune
Discovery Lead 
Optimization IND Enabling Phase 1/1b

Unmasking immune responses in treatment-resistant tumors

name
AGB201 (EDB)
Solid Tumors
Discovery Lead 
Optimization IND Enabling Phase 1/1b

Get in touch

Email Us